Log in
Enquire now
‌

US Patent 9801869 Method of inhibiting constitutively active phosphorylated FLT3 kinase

Patent 9801869 was granted and assigned to Arog Pharmaceuticals, Inc. on October, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Arog Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
0
Current Assignee
Arog Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
98018690
Patent Inventor Names
Vinay K. Jain0
Date of Patent
October 31, 2017
0
Patent Application Number
146716130
Date Filed
March 27, 2015
0
Patent Citations Received
‌
US Patent 11969420 Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
0
‌
US Patent 11713310 Crystal forms of crenolanib and methods of use thereof
0
Patent Primary Examiner
‌
Kevin E. Weddington
0
Patent abstract

The present invention includes a method of inhibiting or reducing deregulated FLT3 tyrosine kinase activity or FLT3 tyrosine kinase expression in a subject with a proliferative disease by administering to the subject having or suspected to have the proliferative disease, a therapeutically or prophylactically effective amount of the compound of Formula I:

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9801869 Method of inhibiting constitutively active phosphorylated FLT3 kinase

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.